

# Andrographis paniculata (Green chiretta) may combat COVID-19

**Keywords:** isolated, naturalized, medicine, properties, antioxidant

**Abbreviations:** HIV, human immunodeficiency-virus infection; AIDS, acquired immunodeficiency syndrome; COVID-19, corona virus disease 2019

## Editorial

*Andrographis paniculata* (Figure 1), known as “Indian echinacea” is an herb used in traditional Chinese medicine and ayurveda. *Andrographis paniculata* is native to India and Sri Lanka but is naturalized in many tropical countries, such as Thailand, Malaysia, Java, and Borneo where it grows isolated patches on roadside, near drain, in between wall cracks, lowlands, hillside, coastlines, and other cultivated or disturbed areas, such as wastelands. It is a bitter-tasting herb rich in compounds known as andrographolides that is hypothesized to have antiviral, anti-inflammatory, and antioxidant properties. This herb is said to act as a natural immune-booster. *Andrographis paniculata* is most widely used to treat cold and flu symptoms and is also used to treat other diseases and symptoms, such as human immunodeficiency-virus infection (HIV)/acquired immunodeficiency syndrome (AIDS), infections, parasitic infestations, sinus infections, cancer, rheumatoid arthritis, hepatic problems, cardiac diseases, anorexia, allergies, ulcers, and skin diseases. Nevertheless, there is not enough scientific evidence to support the use of *Andrographis paniculata* for most of these health benefits. Some preliminary studies demonstrated that *Andrographis paniculata* may offer the health benefits, such as upper respiratory tract infections and ulcerative colitis.



**Figure 1** *Andrographis paniculata* (Green chiretta).

*Andrographis paniculata* may trigger adverse side effects like fatigue, headache, nausea, diarrhea, and allergic reaction. *Andrographis paniculata* should not be administered intravenously due to possible acute renal injury. Individuals using some medications, such as anti-hypertensive medicines, chemotherapy drugs, blood-thinning drugs,

Volume 7 Issue 2 - 2020

Attapon Cheepsattayakorn,<sup>1,2</sup> Ruangrong Cheepsattayakorn<sup>3</sup>

<sup>1</sup>10th Zonal Tuberculosis and Chest Disease Center, Thailand

<sup>2</sup>Faculty of Public Health, St. Theresa International College, Thailand

<sup>3</sup>Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand

**Correspondence:** Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100, Thailand, Tel +66 53 140767/66 53 276364, Fax +66 53 140773/66 53 273590, Email Attapn1958@gmail.com

**Received:** March 12, 2020 | **Published:** March 31, 2020

etc. should consult a clinician before using *Andrographis paniculata*. Little is known about the safety of using *Andrographis paniculata*. There is no single recommended dose of *Andrographis paniculata* due to various dose studies. Some previous studies revealed that for relief of sore throat, a dose of 3-6grams *Andrographis paniculata* was used once a day. For ulcerative colitis, *Andrographis paniculata* extract, 1,200-1,800milligrams was used once a day for eight weeks. For common cold, a combination product (4-5.6milligrams Andrographolide and 400milligrams Siberian ginseng) was used three times daily, whereas another previous study demonstrated using *Andrographis* extract (KalmCold) 200milligrams once a day for 5days. Recently, some Asian countries claimed that *Andrographis paniculata* may kill the COVID-19 and they will initiate studies on this issue in 2020 as soon as possible.

In conclusion, *in vitro* and *in vivo* studies are needed before beginning the clinical trials on killing effects of *Andrographis paniculata* on COVID-19 for clinical safety and its efficacy in patients with COVID-19 infection.

## Acknowledgments

None.

## Conflicts of interest

The authors declare there are no conflicts of interest.

## Funding

None.